Seelos Therapeutics Inc

Seelos Therapeutics Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.5841
  • Today's Change-0.037 / -5.91%
  • Shares traded895.74k
  • 1 Year change-81.04%
  • Beta2.6072
Data delayed at least 15 minutes, as of May 25 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.

  • Revenue in USD (TTM)0.00
  • Net income in USD-60.93m
  • Incorporated1987
  • Employees16.00
  • Location
    Seelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
  • Phone+1 (646) 293-2100
  • Fax+1 (858) 436-8155
  • Websitehttps://seelostherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Codiak BioSciences Inc22.45m-34.88m60.51m102.00--1.25--2.70-1.57-1.571.012.150.1314----220,078.40-20.42---22.18-------155.37-----26.330.3453--686.79--63.75------
Akebia Therapeutics Inc222.97m-275.68m60.57m426.00--2.32--0.2716-1.61-1.611.290.14240.38312.794.47523,410.80-47.37-36.48-74.76-52.8447.2768.21-123.64-94.351.04-12.820.7893---27.68168.3426.24---53.32--
Natural Alternatives International, Inc.162.83m10.57m60.83m220.005.850.71454.080.37361.691.6926.0913.841.284.039.69740,140.908.326.6110.258.1218.5118.176.494.491.7076.560.1039--50.179.35754.592.44-13.33--
DSwiss Inc2.12m133.79k61.62m9.00458.15594.58332.2929.110.00070.00070.01020.00054.6162.5820.89235,156.7033.00-31.31198.66-85.6723.5128.777.16-19.451.0237.390.395--45.3370.191,550.39--2.46--
DiaMedica Therapeutics Inc0.00-13.48m61.88m14.00--1.52-----0.6107-0.61070.001.540.00----0.00-40.49-57.44-42.15-62.64-------9,305.40----0.0004-------10.58--26.14--
SCYNEXIS Inc1.80m-33.64m61.90m56.00--1.43--34.39-1.21-1.210.06411.330.017--1.3732,142.86-31.79-51.44-38.72-62.6077.17---1,868.94-1,299.387.78--0.5336----119.7340.44--112.58--
Seelos Therapeutics Inc0.00-60.93m61.97m16.00--1.35-----0.6016-0.60160.000.43220.00----0.00-108.75-190.52-137.55-336.13-------40,434.13---68.360.2957-------245.78------
Adamis Pharmaceuticals Corp1.97m-30.93m62.05m15.00--3.90--31.50-0.2011-0.26830.01340.10620.03545.011.45131,339.30-55.62-67.59-81.06-91.72-229.4516.94-1,569.87-277.052.04--0.1042---20.45-19.353.48--58.81--
Achieve Life Sciences Inc0.00-32.73m62.45m16.00--2.85-----3.79-3.790.002.260.00----0.00-88.12-68.48-98.05-79.40-----------94.000.4145-------125.06------
BIOQUAL, Inc.64.42m5.50m62.61m108.0011.391.758.730.97196.146.1472.0240.011.15--2.74--9.7912.7711.4414.8422.2123.018.539.65----0.0014.7924.4211.7849.5417.0655.6325.74
ImmuCell Corporation21.14m1.10m63.10m47.0057.771.8917.722.990.14110.14112.724.310.48973.958.38352,258.302.55-2.742.68-2.9348.0646.865.20-7.116.324.970.2466--25.4315.0692.34---6.17--
Bolt Biotherapeutics Inc2.07m-97.82m63.33m91.00--0.2773--30.55-2.64-2.640.05596.100.0068----22,780.22-32.21---33.96-------4,718.52------0.00--445.45---62.35------
CASI Pharmaceuticals Inc33.49m-31.37m63.46m168.00--0.8463--1.89-0.2252-0.22520.24040.55110.24134.164.21199,369.00-22.01-35.38-29.39-43.3358.33---91.23-337.703.53--0.00--99.25--24.09--133.52--
Data as of May 25 2022. Currency figures normalised to Seelos Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

28.31%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 20225.87m5.56%
The Vanguard Group, Inc.as of 31 Mar 20225.46m5.17%
Tontine Associates LLCas of 31 Mar 20224.93m4.67%
Woodline Partners LPas of 31 Mar 20222.80m2.66%
Group One Trading LPas of 31 Mar 20222.24m2.12%
Horizons ETFs Management (Canada), Inc.as of 31 Mar 20221.93m1.83%
SSgA Funds Management, Inc.as of 31 Mar 20221.75m1.65%
Renaissance Technologies LLCas of 31 Mar 20221.72m1.63%
Geode Capital Management LLCas of 31 Mar 20221.62m1.53%
Uniplan Investment Counsel, Inc.as of 31 Mar 20221.56m1.48%
More ▼
Data from 31 Mar 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.